<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04726358</url>
  </required_header>
  <id_info>
    <org_study_id>2019-42</org_study_id>
    <nct_id>NCT04726358</nct_id>
  </id_info>
  <brief_title>ProCaLung: Project on Cancer of the Lung</brief_title>
  <acronym>ProCaLung</acronym>
  <official_title>ProCaLung - Project on Cancer of the Lung : A National Radiotherapy Quality Assurance for Stage III NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Belgian Federal Public Service, Food Chain Safety and Environment</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jules Bordet Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ProCaLung is a national registry collecting radiation treatment parameters of patients having&#xD;
      lung cancer that extends to mediastinal lymph nodes. The project includes a peer review&#xD;
      activity.&#xD;
&#xD;
      The purpose of this public health program is similar to an audit whose objective is to&#xD;
      promote quality of radiation oncology in Belgium. It is run by Institut Jules Bordet on&#xD;
      behalf of the College of Physicians for Radiotherapy Centers of the Belgian Health Federal&#xD;
      Public Service, in close collaboration with the Belgian Cancer Registry.&#xD;
&#xD;
      All Belgian radiotherapy centers are invited to participate in ProCaLung but their&#xD;
      participation is not mandatory. The centers who accept to participate show a commitment to&#xD;
      quality assurance as the radiotherapy-treatment-related parameters they generate will be&#xD;
      analyzed to establish national statistics. It includes a peer-review process based on&#xD;
      international guidelines for mediastinal nodes delineations given for informational purposes.&#xD;
      The public interest program also collects technical parameters as they were planned and&#xD;
      delivered during the course of chest radiation treatment. This includes the delineations of&#xD;
      tumors, nodes and chest organs on simulation-CT images, PET/CT images, chest-CT images and&#xD;
      the clinical information related to the lung cancer. Results/statistics will be published at&#xD;
      the end of the project.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>descriptive statistics for quality assurance (no sample size needed)</measure>
    <time_frame>1 year</time_frame>
    <description>Dosimetry [Non-inferiority, comparison of groups by final review group]: Mean Lung Dose, Lung V20Gy, Lung V30Gy, Mean Heart Dose, Esophagus V60Gy.&#xD;
Waiting times, use of contrast-enhanced CT, ITV, overall treatment time, proportion of treatments with recommended organs at risk delineated, radiological treatment completion rate, chemotherapy (and immunotherapy) completion rate, use of static/rotational intensity modulation, availability of data in the electronic health record.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoints related to standardization</measure>
    <time_frame>1 year</time_frame>
    <description>[Superiority, basis of sample size calculation] CTVn Hausdorff distance 95th percentile (HD95p) &gt; 3mm, calculated between the initial contour of the radiotherapy (RT) center and ProCaLung's review for start and end cohorts.&#xD;
Proportion of treatments with initial review group 1 or 2 in start and end cohorts.&#xD;
Proportion of treatments with final review group 1 or 2 in start and end cohorts.&#xD;
Distribution of indicators of change in start and end cohorts.&#xD;
Conversion rates of review group 3a to review group 1, review group 4 to review group 1, and review group 4 to review group 3a.&#xD;
Distribution of the reasons for the impossibility to review the target definition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoints related to outcomes</measure>
    <time_frame>2 years</time_frame>
    <description>Toxicity [Comparison of final review groups]: Grade 3+ esophageal toxicity, Grade 3+ pulmonary toxicity (clinical and radiological), Other Grade 3+ toxicity.&#xD;
Pattern of locoregional failure (including relation to CTV), progression free survival and overall survival.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Locally Advanced Lung Carcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients treated with thoracic radiotherapy in Belgium for NSCLC with at least one&#xD;
        positive mediastinal node.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed NSCLC only&#xD;
&#xD;
          -  Locally advanced disease (Stage III) with positive mediastinal nodes&#xD;
&#xD;
          -  PET/CT staged&#xD;
&#xD;
          -  Curative intent radiotherapy&#xD;
&#xD;
          -  Chemotherapy (ChT): Without, Sequential ChT - Radiotherapy (RT) (max 2 cycles),&#xD;
             Concurrent (± induction ChT)&#xD;
&#xD;
          -  Prescription dose ≥ 60 Gy (EQD2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of thoracic RT&#xD;
&#xD;
          -  Malignant pleural effusion&#xD;
&#xD;
          -  History of malignancy in the last 3 years, except basal-cell skin cancer and&#xD;
             intra-epithelial neoplasia&#xD;
&#xD;
          -  Progression after induction chemotherapy&#xD;
&#xD;
          -  Use of concurrent targeted, immunomodulating or anti-angiogenic agents except if the&#xD;
             patient is included in a clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luigi Moretti, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Belgian College of Physicians for Radiation Oncology Centers</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luigi Moretti, MD, PhD</last_name>
    <phone>+3225413800</phone>
    <email>Luigi.moretti@bordet.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Florian Charlier, MD</last_name>
    <phone>+325413800</phone>
    <email>Florian.charlier@bordet.be</email>
  </overall_contact_backup>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>Radiation therapy</keyword>
  <keyword>Mediastinal adenopathy</keyword>
  <keyword>Quality assurance</keyword>
  <keyword>Delineation</keyword>
  <keyword>National registry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

